论文部分内容阅读
目的观察抗肿瘤新药去甲长春花碱（Ｎａｖｅｌｂｉｎｅ，ＮＶＢ）加顺铂（Ｃｉｓｐｌａｔｉｎ，ＤＤＰ）联合化疗治疗晚期非小细胞肺癌（ＮｏｎＳｍａｌｃｅｌＬｕｎｇｃａｎｃｅｒ，ＮＳＣＬＣ）的疗效。方法ＮＶＢ联合ＤＤＰ治疗ＮＳＣＬＣ３２例，各例至少治疗２个周期，男性２３例，女性９例。病理类型以腺癌为主（１８例），Ⅲａ期５例，Ⅲｂ８例，Ⅳ１９例。结果部分缓解（ＰＲ）２１例，稳定（Ｓ）５例，进展（Ｐ）６例，总有效率６５．６％，ＮＶＢ的剂量限制毒性为骨髓抑制。白细胞下降占１００．０％，其中Ⅲ、Ⅳ度为６５．６％。注射局部静脉毒性发生率３７．５％。结论ＮＶＢ联合ＤＤＰ治疗晚期ＮＳＣＬＣ具有较高疗效、毒性可以耐受等特点，可进一步推广应用
Objective To observe the efficacy of antitumor drug Navelbine (NVB) plus Cisplatin (DDP) combined with chemotherapy for advanced non-small cell lung cancer (NSCLC). Methods Thirty-two patients with NSCLC were treated with NVB combined with DDP. Each case received at least 2 cycles. There were 23 males and 9 females. The main pathological types were adenocarcinoma (18 cases), 5 cases in stage IIIa, 8 cases in IIIb, and 19 cases in IV. Results Partial remission (PR) in 21 cases, stable (S) in 5 cases, progression (P) in 6 cases, total effective rate was 65.6%, NVB dose-limiting toxicity was myelosuppression. Leukocyte decline accounted for 100.0%, of which III and IV were 65.6%. The incidence of local venous toxicity was 37.5%. Conclusion NVB combined with DDP has advantages in the treatment of advanced NSCLC with high efficacy and tolerability. It can be further promoted and applied.